Literature DB >> 25805832

A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.

Mohamed F Salama1, Brittany Carroll1, Mohamad Adada1, Michael Pulkoski-Gross1, Yusuf A Hannun1, Lina M Obeid2.   

Abstract

Sphingosine kinase 1 (SK1), the enzyme responsible for sphingosine 1-phosphate (S1P) production, is overexpressed in many human solid tumors. However, its role in clear cell renal cell carcinoma (ccRCC) has not been described previously. ccRCC cases are usually associated with mutations in von Hippel-Lindau (VHL) and subsequent normoxic stabilization of hypoxia-inducible factor (HIF). We previously showed that HIF-2α up-regulates SK1 expression during hypoxia in glioma cells. Therefore, we hypothesized that the stabilized HIF in ccRCC cells will be associated with increased SK1 expression. Here, we demonstrate that SK1 is overexpressed in 786-0 renal carcinoma cells lacking functional VHL, with concomitant high S1P levels that appear to be HIF-2α mediated. Moreover, examining the TCGA RNA seq database shows that SK1 expression was ∼2.7-fold higher in solid tumor tissue from ccRCC patients, and this was associated with less survival. Knockdown of SK1 in 786-0 ccRCC cells had no effect on cell proliferation. On the other hand, this knockdown resulted in an ∼3.5-fold decrease in invasion, less phosphorylation of focal adhesion kinase (FAK), and an ∼2-fold decrease in angiogenesis. Moreover, S1P treatment of SK1 knockdown cells resulted in phosphorylation of FAK and invasion, and this was mediated by S1P receptor 2. These results suggest that higher SK1 and S1P levels in VHL-defective ccRCC could induce invasion in an autocrine manner and angiogenesis in a paracrine manner. Accordingly, targeting SK1 could reduce both the invasion and angiogenesis of ccRCC and therefore improve the survival rate of patients. © FASEB.

Entities:  

Keywords:  HIF-2; S1P receptor; focal adhesion kinase; sphingosine 1-phosphate

Mesh:

Substances:

Year:  2015        PMID: 25805832      PMCID: PMC4478804          DOI: 10.1096/fj.15-270413

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  65 in total

Review 1.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.

Authors:  Shi-Quan Liu; Ying-Jie Su; Meng-Bin Qin; Ye-Bo Mao; Jie-An Huang; Guo-Du Tang
Journal:  Int J Oncol       Date:  2012-12-12       Impact factor: 5.650

4.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

Authors:  Peter Schraml; Kirsten Struckmann; Florian Hatz; Stefan Sonnet; Charlotte Kully; Thomas Gasser; Guido Sauter; Michael J Mihatsch; Holger Moch
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

Review 5.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

6.  Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes.

Authors:  S M Pitson; R J D'andrea; L Vandeleur; P A Moretti; P Xia; J R Gamble; M A Vadas; B W Wattenberg
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

7.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

8.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

Authors:  Eugen Ruckhäberle; Achim Rody; Knut Engels; Regine Gaetje; Gunter von Minckwitz; Susanne Schiffmann; Sabine Grösch; Gerd Geisslinger; Uwe Holtrich; Thomas Karn; Manfred Kaufmann
Journal:  Breast Cancer Res Treat       Date:  2007-12-04       Impact factor: 4.872

9.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

10.  Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling.

Authors:  Vermont P Dia; Elvira Gonzalez de Mejia
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

View more
  26 in total

1.  Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.

Authors:  Cheng-Fan Lee; Andrew Dang; Elizabeth Hernandez; Rey-Chen Pong; Benjamin Chen; Rajni Sonavane; Ganesh Raj; Payal Kapur; Hsin-Ying Lin; Shang-Ru Wu; Chun-Jung Ko; U-Ging Lo; Hsin-Yu Lee; Jer-Tsong Hsieh; Ming-Shyue Lee
Journal:  Oncogene       Date:  2019-05-31       Impact factor: 9.867

Review 2.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

3.  The unmasking of the lipid binding face of sphingosine kinase 1.

Authors:  Robert V Stahelin
Journal:  J Lipid Res       Date:  2018-01-30       Impact factor: 5.922

4.  An intrinsic lipid-binding interface controls sphingosine kinase 1 function.

Authors:  Michael J Pulkoski-Gross; Meredith L Jenkins; Jean-Philip Truman; Mohamed F Salama; Christopher J Clarke; John E Burke; Yusuf A Hannun; Lina M Obeid
Journal:  J Lipid Res       Date:  2018-01-11       Impact factor: 5.922

5.  Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma.

Authors:  Yunze Xu; Baijun Dong; Jianfeng Wang; Jin Zhang; Wei Xue; Yiran Huang
Journal:  Oncoimmunology       Date:  2018-09-25       Impact factor: 8.110

6.  Hispidulin suppresses tumor growth and metastasis in renal cell carcinoma by modulating ceramide-sphingosine 1-phosphate rheostat.

Authors:  Ming-Quan Gao; Hui Gao; Mei Han; Kai-Li Liu; Jian-Jun Peng; Yan-Tao Han
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 7.  Sphingolipids in mitochondria.

Authors:  María José Hernández-Corbacho; Mohamed F Salama; Daniel Canals; Can E Senkal; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-30       Impact factor: 4.698

8.  Hispidulin mediates apoptosis in human renal cell carcinoma by inducing ceramide accumulation.

Authors:  Hui Gao; Ming-Quan Gao; Jian-Jun Peng; Mei Han; Kai-Li Liu; Yan-Tao Han
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

9.  Probing de novo sphingolipid metabolism in mammalian cells utilizing mass spectrometry.

Authors:  Justin M Snider; Ashley J Snider; Lina M Obeid; Chiara Luberto; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

Review 10.  Bioactive lysolipids in cancer and angiogenesis.

Authors:  Yu Hisano; Timothy Hla
Journal:  Pharmacol Ther       Date:  2018-07-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.